source
- Inhibrx says combo therapy shrank more tumors than Merck's Keytruda aloneSan Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more t…Endpoints · 2mo ago↗ source
- Treatment Intensification Gains Momentum in mCSPC ManagementDuring a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.onclive · 2mo ago↗ source
- FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety ConsiderationsLuhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.